Dealroom: HHC puts Al Huqbani over 33M Saudi beneficiaries, and UAE operators should watch

Saudi Arabia's Health Holding Company (HHC) is being run by Nasser Al Huqbani, the former Dr. Sulaiman Al Habib Medical Services Group (HMG) executive linked by Dealroom to a hospital group valued at $21.9 billion, giving one private-sector operator influence over public care delivery for more than 33 million Saudi beneficiaries.

For UAE readers, the story matters most to CEOs, CFOs and COOs. Dubai clinics should read it as a scale warning. Abu Dhabi insurers should read it as a purchasing signal. Northern Emirates operators should read it as evidence that Riyadh wants health clusters to behave more like accountable systems than ministry departments. The relevant UAE regulators remain the Dubai Health Authority (DHA), the Department of Health Abu Dhabi (DOH) and the Ministry of Health and Prevention (MOHAP).

What Saudi Arabia has hired

HHC says it was established on 2 June 2022 after Cabinet Resolution No. 469, with a mandate to move Ministry of Health assets into a corporatised structure. Its official profile names Nasser bin Mohammed Al-Haqbani as chief executive officer and says HHC provides services to more than 20 million people through 20 health clusters. In a 2025 interview with Oxford Business Group, Al Huqbani said health coverage had reached 97.4%, or more than 33 million beneficiaries.

Al Huqbani's private-sector record is the point. HMG floated 52.5 million shares, equal to 15% of its capital, in March 2020. The offer price was SAR 50 a share, raising about SAR 2.63 billion ($700 million). Argaam reported that the IPO was subscribed about 83 times, with funds exceeding SAR 217 billion. Dealroom frames that history as the reason his HHC role deserves attention.

Why Dubai operators should care first

Dubai is the UAE market most exposed to regional patient flows, private network competition and specialist-brand comparison. DHA said licensed healthcare facilities in Dubai reached about 5,800 in 2025, up from 5,340 in 2024, according to the Dubai Media Office. That is a crowded market. A larger Saudi public purchaser can change referral economics if it keeps more oncology, cardiology, rehabilitation and elective work inside Saudi Arabia.

The immediate risk is limited for day-to-day primary care in Dubai, because mandatory insurance networks and DHA licensing still govern local access. The strategic risk is different. If HHC uses its 20 clusters to buy equipment, digital systems and clinical services centrally, suppliers and hospital groups may prioritise Saudi procurement cycles over smaller UAE tenders. CIOs should track HHC digital requirements because Sehhaty and Seha Virtual Hospital already give Saudi Arabia a national distribution channel that few UAE private groups can match alone.

• Dubai clinics: audit Saudi patient volumes by specialty and payer before planning new capacity.
• Insurers: compare cross-border authorisation rules for Daman, Thiqa and Sukoon members before changing network strategy.
• Hospital CFOs: test downside cases for high-margin tertiary referrals over the next 12 to 24 months.
• Health-tech vendors: map product fit to HHC cluster procurement and UAE regulator integration rules.

What changes for Abu Dhabi and the northern emirates

Abu Dhabi has a different exposure. DOH oversees a system with large public and semi-public hospital assets, including SEHA facilities and tertiary centres. Its insurers, including Daman and Thiqa, already operate in a more structured reimbursement environment than many outpatient-heavy Dubai networks. The Saudi lesson for Abu Dhabi is procurement discipline. A single national buyer can push harder on data standards, utilisation review and value-based contracts than fragmented payers can.

For MOHAP-regulated providers in Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, the signal is workforce and catchment competition. Saudi clusters will need clinicians, nurses, revenue-cycle staff and IT implementation teams. UAE HR heads should treat Saudi recruitment as a live retention issue, particularly for Arabic-speaking clinicians and administrators with GCC licensing experience. Salary ranges cannot be stated reliably without role, grade, specialty and benefits data. Operators should benchmark against signed offers, regulator licensing data and recruiter shortlists, then separate cash salary from housing, schooling and rotation terms.

Pricing needs the same discipline. There is no universal UAE tariff that applies across DHA, DOH and MOHAP settings. Dubai operators should pull allowed amounts and denial rates from eClaimLink data. Abu Dhabi providers should use payer contracts and DOH reimbursement rules. Northern Emirates clinics should check MOHAP licensing status and each insurer's live network file before quoting patient-facing packages.

The practical step is simple. Treat HHC as a regional competitor, buyer and possible partner, then quantify the exposure by specialty, payer and nationality mix. UAE patients and operators can check licensed hospitals and providers through the UAE Open Healthcare Directory, which lists more than 12,386 providers anchored to DHA, DOH Abu Dhabi and MOHAP registers.